LivaNova PLC, a leading medical technology company, has reported its financial results for the second quarter ended June 30, 2025. The company achieved a revenue of $352.5 million, marking a 10.7% increase on a reported basis and a 9.3% rise on a constant-currency basis compared to the same period in the previous year. Additionally, the revenue saw a 10.3% growth on an organic basis. The second quarter also showed an improvement in earnings, with U.S. GAAP diluted earnings per share at $0.50, up from $0.30 in the second quarter of 2024. Adjusted diluted earnings per share were reported at $1.05, compared to $0.93 in the prior-year period. The net cash provided by operating activities was $62.9 million, and adjusted free cash flow was recorded at $47.8 million. LivaNova has revised its full-year 2025 guidance, expecting revenue growth to be between 8.0% and 9.0% on a constant-currency basis, and between 9.0% and 10.0% on an organic basis. The company has also adjusted its projected diluted earnings per share range, now expected to be between $3.70 and $3.80. Significantly, LivaNova has initiated a process with the U.S. Centers for Medicare and Medicaid Services for reconsideration of national coverage for VNS Therapy™ for treatment-resistant depression. The company also announced long-term, real-world evidence supporting the efficacy of VNS Therapy in treating a range of seizure types in individuals with drug-resistant epilepsy.